![Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein | Nature Neuroscience Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein | Nature Neuroscience](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41593-022-01239-7/MediaObjects/41593_2022_1239_Fig1_HTML.png)
Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein | Nature Neuroscience
![Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial - The Lancet Infectious Diseases Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/5588ae13-d0b2-4417-9ed6-18f5e41fb5c7/gr1.jpg)
Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial - The Lancet Infectious Diseases
![Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial - The Lancet Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/6d181332-b916-4758-a2fc-707eb4ab0d71/gr1.jpg)
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial - The Lancet
![NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62 | Nature Communications NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62 | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-023-44033-0/MediaObjects/41467_2023_44033_Fig1_HTML.png)
NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62 | Nature Communications
![Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial - The Lancet Healthy Longevity Bimagrumab to improve recovery after hip fracture in older adults: a multicentre, double-blind, randomised, parallel-group, placebo-controlled, phase 2a/b trial - The Lancet Healthy Longevity](https://www.thelancet.com/cms/asset/e9543d2d-077b-4951-9cb4-c1acc9dd2073/gr1.jpg)